PLATFORMS◐ DEVELOPINGI · Intelligence▽ Strained
Claude failed to generate scorpion antivenom in drug-development trial
Oct 22, 2026SOURCE: theverge.com
SO WHAT
This is a signal that the window for human-led drug creation still matters; AI outputs may nucleate hypotheses, but the old system retains bottlenecks that define winners.
An investment firm tested an unreleased Anthropic Claude against scorpion antivenom. The inversion hit limits: ideas surfaced, but no viable drug emerged.
This is Negative Resistance’s reframed reading of a reported signal. The headline and analysis above are our interpretation through the thousand-day-window lens. The original reporting lives at the source linked above.